MedTrace Logo

Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis

NCT06063785 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-10-23

No results posted yet for this study

Summary

Cystic fibrosis (CF) is the most common hereditary disease in Central Europe. The disease is caused by a mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR). In the liver, fibrotic remodeling can lead to liver cirrhosis in the long term. Early detection of CF hepatopathy is essential to therapeutically slow down the progression of fibrotic remodeling mechanisms. Newborns suffering from CF have a significantly increased risk for the occurrence of meconium ileus and also with advancing age there are symptoms ranging from chronic constipation to Distal Intestinal Obstruction Syndrome (DIOS), due to a reduction of intestinal motility.

In this study, the degree of liver fibrosis will now be investigated in adult patients with cystic fibrosis using Multispectral Optoacoustic Imaging (MSOT). In addition, gastrointestinal passage will be studied non-invasively to investigate another affection of the gastrointestinal system.

Conditions

Interventions

DIAGNOSTIC_TEST

Acoustic Radiation Forced Impulse Imaging

Measurement of Liver stiffness

DIAGNOSTIC_TEST

Multispectral Optoacoustic Tomography

Measurement of optoacoustic spectra in liver and gastrointestinal tract

Sponsors & Collaborators

  • Adrian Regensburger

    collaborator UNKNOWN

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Alexander Schnell · Department of Pediatric and Adolescent Medicine, University Hospital Erlangen

  • Adrian P Regensburger · Department of Pediatric and Adolescent Medicine, University Hospital Erlangen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-09-30
Completion
2025-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06063785 on ClinicalTrials.gov